For people with chronic migraine, taking glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, for other conditions such as diabetes and weight loss, was associated with fewer emergency department visits and hospitalizations overall, and with less need for medications used to stop and prevent migraine attacks, according to a preliminary study released March 1, 2026, that will be presented at the American Academy of Neurology’s 78th Annual Meeting taking place April 18-22, 2026, in Chicago and online.